Syntopix signs new deal with Sinclair Pharma

SKIN treatment development specialist Syntopix announced today that it has signed a second deal with Sinclair Pharma, a leading skin and mouth disease specialist with sales and marketing operations across Europe.

Sinclair will pay Bradford-based Syntopix a development contract fee to further develop combination formulations using Sinclair’s delmopinol.

At the end of the development programme, if any of the formulations for oral health and other medical applications are commercialised, Syntopix will receive royalties.

This builds on an initial agreement between the companies announced in April to work together on the identification of an antimicrobial compound to synergise and augment the anti-biofilm activity of Sinclair’s key ingredient already marketed as Decapinol.

Dr Stephen Jones, chief executive of Syntopix, said: “I am delighted that the collaboration Syntopix and Sinclair embarked on in April has been a success. We have been working closely with Sinclair and are pleased to be able to progress our agreement to the next stage.

“As a leading company developing treatments for diseases/problems of the skin and mouth, Sinclair’s expertise is closely aligned with our own and together we are in a strong position to develop unique and effective products.”